Header and Body 3

Technology

Current invention uses quantitative mass spectrometric profiling of ECM proteins of non-metastatic primary tumors and metastatic tumors compared to normal tissue. This allowed for generation of signature sets of ECM proteins that are deregulated in tumors and also between different progression stages of cancer. These signature sets can be used to profile progression stage of cancer biopsies. Using antibodies targeted against the proteins in the signature sets, it is also possible to deliver conjugated agents such as imaging agents or chemotherapeutic agents for imaging and treatment of cancer.